Neuronetics Q3 2026 revenue up 12.5% to $42.0M
Neuronetics reported strong Q3 2026 results with total revenue up 12.5%, despite a net loss of $1.6 million, as both NeuroStar device sales and Greenbrook clinic operations showed year-over-year growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed